Search

Your search keyword '"López-Campos, José Luis"' showing total 352 results
Start Over Author "López-Campos, José Luis" Language english
352 results on '"López-Campos, José Luis"'

2. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

Author

Agusti, Alvar, Lopez-Campos, José Luis, Miravitlles, Marc, Soler-Cataluña, Juan Jose, Marin, Jose Maria, Cosio, Borja G., Alcázar-Navarrete, Bernardino, Echave-Sustaeta, Jose Maria, Casanova, Ciro, Peces-Barba, German, de-Torres, Juan Pablo, Fernandez-Villar, Alberto, Ancochea, Julio, Villar-Alvarez, Felipe, Roman-Rodriguez, Miguel, Molina, Jesus, Garcia-Rivero, Juan Luis, Gonzalez, Cruz, Sobradillo, Patricia, Faner, Rosa, Peña, Carolina, Sharma, Raj, Izquierdo, José Luis, and Celli, Bartolome R.

Published
2024
Full Text
View/download PDF

3. Heteroatom-tagged proteomics of lung cancer and chronic obstructive pulmonary disease human serum reveal alterations in selenoproteins

Author

Callejón-Leblic, Belén, Sánchez Espirilla, Saida, Gotera-Rivera, Carolina, Santana, Rafael, Díaz-Olivares, Isabel, María Marín Trigo, José, Casanova Macario, Ciro, Cosio, Borja G., Fuster, Antonia, Solanes García, Ingrid, de-Torres, Juan P., Feu Collado, Nuria, Cabrera Lopez, Carlos, Amado Diago, Carlos, Romero Plaza, Amparo, Padrón Fraysse, Luis Alejandro, Márquez Martín, Eduardo, Marín Royo, Margarit, Balcells Vilarnau, Eva, Llunell Casanovas, Antonia, Martínez González, Cristina, Bautista Galdíz Iturri, Juan, Lacárcel Bautista, Celia, Gómez-Ariza, José Luis, Pereira-Vega, Antonio, Seijo, Luis, López-Campos, José Luis, Peces-Barba, Germán, and García-Barrera, Tamara

Published
2024
Full Text
View/download PDF

4. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients

Author

Calle Rubio, Myriam, López-Campos, José Luis, Miravitlles, Marc, Michel de la Rosa, Francisco Javier, Hernández Pérez, José María, Montero Martínez, Carmen, Montoro Ronsano, José Bruno, Casas Maldonado, Francisco, Rodríguez Hermosa, Juan Luis, Tabernero Huguet, Eva María, Martínez Sesmero, José Manuel, Martínez Rivera, Carlos, Callejas González, Francisco Javier, and Torres Durán, María

Published
2023
Full Text
View/download PDF

5. Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

Author

Miravitlles, Marc, Turner, Alice M., Torres-Duran, María, Tanash, Hanan, Rodríguez-García, Carlota, López-Campos, José Luis, Chlumsky, Jan, Guimaraes, Catarina, Rodríguez-Hermosa, Juan Luis, Corsico, Angelo, Martinez-González, Cristina, Hernández-Pérez, José María, Bustamante, Ana, Parr, David G., Casas-Maldonado, Francisco, Hecimovic, Ana, Janssens, Wim, Lara, Beatriz, Barrecheguren, Miriam, González, Cruz, Stolk, Jan, Esquinas, Cristina, and Clarenbach, Christian F.

Published
2023
Full Text
View/download PDF

7. Sex-Differences in Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry

Author

Ersöz, Hilal, Torres-Durán, María, Turner, Alice M., Tanash, Hanan, García, Carlota Rodríguez, Corsico, Angelo Guido, López-Campos, José Luis, Miravitlles, Marc, Clarenbach, Christian F., Chapman, Kenneth R., Pérez, Jose Mª Hernández, Guimarães, Catarina, Bartošovská, Eva, Greulich, Timm, Barrecheguren, Miriam, Koczulla, Andreas Rembert, Höger, Philipp, Rivera, Arturo Olivares, Herth, Felix, and Trudzinski, Franziska C.

Published
2024
Full Text
View/download PDF

14. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

Author

Miravitlles, Marc, Turner, Alice M., Torres-Duran, María, Tanash, Hanan, Rodríguez-García, Carlota, López-Campos, José Luis, Chlumsky, Jan, Guimaraes, Catarina, Rodríguez-Hermosa, Juan Luis, Corsico, Angelo, Martinez-González, Cristina, Hernández-Pérez, José María, Bustamante, Ana, Parr, David G., Casas-Maldonado, Francisco, Hecimovic, Ana, Janssens, Wim, Lara, Beatriz, Barrecheguren, Miriam, González, Cruz, Stolk, Jan, Esquinas, Cristina, and Clarenbach, Christian F.

Published
2022
Full Text
View/download PDF

18. A Pilot Study on Proteomic Predictors of Mortality in Stable COPD.

Author

Enríquez-Rodríguez, Cesar Jessé, Casadevall, Carme, Faner, Rosa, Pascual-Guardia, Sergi, Castro-Acosta, Ady, López-Campos, José Luis, Peces-Barba, Germán, Seijo, Luis, Caguana-Vélez, Oswaldo Antonio, Monsó, Eduard, Rodríguez-Chiaradia, Diego, Barreiro, Esther, Cosío, Borja G., Agustí, Alvar, Gea, Joaquim, and Group, on behalf of the BIOMEPOC

Subjects
CHRONIC obstructive pulmonary disease, PEPTIDE mass fingerprinting, ARTIFICIAL intelligence, PROTEOMICS, DEATH forecasting
Abstract

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global mortality. Despite clinical predictors (age, severity, comorbidities, etc.) being established, proteomics offers comprehensive biological profiling to obtain deeper insights into COPD pathophysiology and survival prognoses. This pilot study aimed to identify proteomic footprints that could be potentially useful in predicting mortality in stable COPD patients. Plasma samples from 40 patients were subjected to both blind (liquid chromatography–mass spectrometry) and hypothesis-driven (multiplex immunoassays) proteomic analyses supported by artificial intelligence (AI) before a 4-year clinical follow-up. Among the 34 patients whose survival status was confirmed (mean age 69 ± 9 years, 29.5% women, FEV1 42 ± 15.3% ref.), 32% were dead in the fourth year. The analysis identified 363 proteins/peptides, with 31 showing significant differences between the survivors and non-survivors. These proteins predominantly belonged to different aspects of the immune response (12 proteins), hemostasis (9), and proinflammatory cytokines (5). The predictive modeling achieved excellent accuracy for mortality (90%) but a weaker performance for days of survival (Q2 0.18), improving mildly with AI-mediated blind selection of proteins (accuracy of 95%, Q2 of 0.52). Further stratification by protein groups highlighted the predictive value for mortality of either hemostasis or pro-inflammatory markers alone (accuracies of 95 and 89%, respectively). Therefore, stable COPD patients' proteomic footprints can effectively forecast 4-year mortality, emphasizing the role of inflammatory, immune, and cardiovascular events. Future applications may enhance the prognostic precision and guide preventive interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

Author

Adeloye, Davies, Elneima, Omer, Daines, Luke, Poinasamy, Krisnah, Quint, Jennifer K, Walker, Samantha, Brightling, Chris E, Siddiqui, Salman, Hurst, John R, Chalmers, James D, Pfeffer, Paul E, Novotny, Petr, Drake, Thomas M, Abdollahi, Mohammad, Agarwal, Dhiraj, Al-Lehebi, Riyad, Barnes, Peter J, Bayry, Jagadeesh, Bonay, Marcel, Bont, Louis J, Bourdin, Arnaud, Brown, Thomas, Caramori, Gaetano, Chan, Amy Hai Yan, Dockrell, David H, Doe, Simon, Duckers, Jamie, D'Urzo, Anthony, Ekström, Magnus, Esteban, Cristóbal, Greene, Catherine M, Gupta, Atul, Ingram, Jennifer L, Khoo, Ee Ming, Ko, Fanny Wai San, Koppelman, Gerard H, Lipworth, Brian J, Lisspers, Karin, Loebinger, Michael, Lopez-Campos, Jose Luis, Maddocks, Matthew, Mannino, David, Martinez-Garcia, Miguel A, Mcnamara, Renae, Miravitlles, Marc, Ndarukwa, Pisirai, Pooler, Alison, Rhee, Chin Kook, Schwarz, Peter, Shaw, Dominick, Steiner, Michael, Tai, Andrew, Ulrik, Charlotte Suppli, Walker, Paul, Williams, Michelle C, Heaney, Liam G, Rudan, Igor, Sheikh, Aziz, and De Soyza, Anthony

Published
2021
Full Text
View/download PDF

24. Occult cancer in patients with unprovoked venous thromboembolism: A nested case-control study.

Author

Sánchez-López, Verónica, Marín-Romero, Samira, Ferrer-Galván, Marta, Elías-Hernández, Teresa, Beristain, José Luis Lobo, Quincoces, Aitor Ballaz, Jara-Palomares, Luis, Martorell, Francisco Javier Rodríguez, Castro, María José, Hinojosa, Carmen Marín, López-Campos, José Luis, and Otero-Candelera, Remedios

Subjects
THROMBOEMBOLISM, OCCULTISM, CANCER patients, CASE-control method, FIBRIN fragment D
Abstract

Objectives Detecting occult cancer in patients with unprovoked venous thromboembolism (VTE) remains a significant challenge. Our objective was to investigate the potential predictive role of coagulation-related biomarkers in the diagnosis of occult malignancies. Methods We conducted a nested case-control study with a 1-year prospective cohort of 214 patients with unprovoked VTE, with a focus on identifying occult cancer. At the time of VTE diagnosis, we measured various biomarkers, including soluble P-selectin (sP-selectin), dimerized plasmin fragment D (D-dimer), platelets, leukocytes, hemoglobin, total extracellular vesicles (EVs), EVs expressing tissue factor on their surface (TF+EVs), and EVs expressing P-selectin on their surface (Psel+EVs) in all participants. Results We observed statistically significant increased levels of sP-selectin (P =.015) in patients with occult cancer. Despite an increase in Psel+EVs, TF+EVs, D-dimer, and platelets within this group, however, no significant differences were found. When sP-selectin exceeded 62 ng/mL and D-dimer surpassed 10,000 µg/L, the diagnosis of occult cancer demonstrated a specificity of up to 91% (95% CI, 79.9%-96.7%). Conclusions The combination of sP-selectin and D-dimer can be a valuable biomarker in detecting occult cancer in patients with unprovoked VTE. Further research is necessary to ascertain whether easily measurable biomarkers such as sP-selectin and D-dimer can effectively distinguish between patients who have VTE with and without hidden malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case–Control Study With Follow-Up

Author

Borràs-Santos, Alícia, Garcia-Aymerich, Judith, Soler-Cataluña, Juan José, Vigil Giménez, Laura, Gea Guiral, Joaquim, Rodríguez Chiaradía, Diego, Pascual-Guardia, Sergi, Marcos Rodríguez, Pedro J., Alvarez Martinez, Carlos J., Casanova Macario, Ciro, López-Campos, José Luis, Carrasco Hernández, Laura, Martínez-González, Cristina, Santos-Pérez, Salud, Peces-Barba, Germán, Molina Paris, Jesús, Román Rodríguez, Miguel, Barberà, Joan Albert, Faner, Rosa, Agustí, Alvar, and Cosío, Borja G.

Published
2019
Full Text
View/download PDF

27. The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Author

Gea, Joaquim, Pascual, Sergi, Castro-Acosta, Ady, Hernández-Carcereny, Carmen, Castelo, Robert, Márquez-Martín, Eduardo, Montón, Concepción, Palou, Alexandre, Faner, Rosa, Furlong, Laura I., Seijo, Luis, Sanz, Ferran, Torà, Montserrat, Vilaplana, Carles, Casadevall, Carme, López-Campos, José Luis, Monsó, Eduard, Peces-Barba, Germán, Cosío, Borja G., Agustí, Alvar, Admetlló, Mireia, Alvarez-Martínez, Carlos, Barreiro, Esther, Casals, Ferran, Córdova, Rocío, García, Marian, González-García, José G., Márquez, Eduardo, Ormaza, Miren Josune, Puigdevall, Pau, Seijó, Luis, and Torralba, Yolanda

Published
2019
Full Text
View/download PDF

29. Detection of Alpha-1 Antitrypsin Levels in Chronic Obstructive Pulmonary Disease in Respiratory Clinics in Spain: Results of the EPOCONSUL 2021 Audit.

Author

Calle Rubio, Myriam, Miravitlles, Marc, López-Campos, José Luis, Soler-Cataluña, Juan J., Alcazar Navarrete, Bernardino, Fuentes-Ferrer, Manuel E., and Rodriguez Hermosa, Juan Luis

Subjects
CHRONIC obstructive pulmonary disease, ALPHA 1-antitrypsin deficiency, RESPIRATORY diseases, TRYPSIN inhibitors, MEDICAL registries, AUDITING
Abstract

Background: Alpha-1 antitrypsin deficiency (AATD) is an underdiagnosed condition despite being one of the most common inherited disorders in adults that is associated with an increased risk of developing chronic obstructive pulmonary disease (COPD). The aim was to evaluate the frequency of performing AAT levels and associated factors in COPD patients in an audit conducted in 2021–2022, as well as to compare with a previous audit conducted in 2014–2015. Methods: EPOCONSUL 2021 is a cross-sectional audit that evaluated the outpatient care provided to COPD patients in respiratory clinics in Spain based on available data from medical registries. Results: 4225 patients with a diagnosis of COPD from 45 centers were audited in 2021. A total of 1670 (39.5%) patients underwent AAT determination. Being treated at a specialized COPD outpatient clinic (OR 1.88, p = 0.007), age ≤ 55 years old (OR 1.84, p = 0.007) and a FEV1 < 50% (OR 1.86, p < 0.001) were associated with a higher likelihood of being tested for AAT, while Charlson index ≥ 3 (OR 0.63, p < 0.001) and genotyping of AATD availability (OR 0.42, p < 0.001) showed a statistically significant negative association. The analysis of cases included in respiratory units that participated in both audits showed an increase in the proportion of cases with AAT serum level testing available (adjusted OR 2.81, p < 0.001). The percentage of individuals with serum AAT levels < 60 mg/dL (a severe AATD) was 4%. Conclusions: Our analysis identifies significant improvements in adherence to the recommendation to test AAT levels in COPD patients, performed in 4 out of 10 patients, being more likely at younger ages and with higher COPD severity, and with a detection of severe AATD of 4% among those tested, suggesting that clinicians still perform AAT testing in COPD patients selectively. Therefore, efforts are still needed to optimize AATD screening and establish new early detection strategies to reduce morbidity and mortality in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO.

Author

Stockley, Robert A., Pye, Anita, De Soyza, Joshua, Turner, Alice M., Miravitlles, Marc, the EARCO study investigators, Torres-Duran, María, Tanash, Hanan, Rodríguez-García, Carlota, López-Campos, José Luis, Chlumsky, Jan, Guimaraes, Catarina, Rodríguez-Hermosa, Juan Luis, Corsico, Angelo, Martinez-González, Cristina, Hernández-Pérez, José María, Bustamante, Ana, Parr, David G., Casas-Maldonado, Francisco, and Hecimovic, Ana

Subjects
ALPHA 1-antitrypsin, BRONCHIECTASIS, TRYPSIN inhibitors, COMPUTED tomography
Abstract

Background: Although bronchiectasis has been recognised as a feature of some patients with Alpha1-Antitrypsin deficiency the prevalence and characteristics are not widely known. We wished to determine the prevalence of bronchiectasis and patient characteristics. The first cohort of patients recruited to the EARCO (European Alpha1 Research Collaboration) International Registry data base by the end of 2021 was analysed for radiological evidence of both emphysema and bronchiectasis as well as baseline demographic features. Results: Of the first 505 patients with the PiZZ genotype entered into the data base 418 (82.8%) had a reported CT scan. There were 77 (18.4%) with a normal scan and 38 (9.1%) with bronchiectasis alone. These 2 groups were predominantly female never smokers and had lung function in the normal range. The remaining 303 (72.5%) ZZ patients all had emphysema on the scan and 113 (27%) had additional evidence of bronchiectasis. Conclusions: The data indicates the bronchiectasis alone is a feature of 9.1% of patients with the PiZZ genotype of Alpha1-antitrypsin deficiency but although emphysema is the dominant lung pathology bronchiectasis is also present in 27% of emphysema cases and may require a different treatment strategy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Smoking and COPD Knowledge in the General Spanish Population: A CONOCEPOC Study.

Author

Rodríguez Hermosa, Juan Luis, Miravitlles, Marc, López-Campos, José Luis, and Calle Rubio, Myriam

Subjects
SMOKING, SMOKE prevention, CHRONIC obstructive pulmonary disease, SMOKING prevention, ELECTRONIC cigarettes
Abstract

Background: The objective of this analysis is to evaluate tobacco use and the level of chronic obstructive pulmonary disease (COPD) knowledge among the general adult population in Spain and to compare these results to those obtained in the 2011 survey. Methods: A cross-sectional, observational, epidemiological study was conducted by telephone interviews and stratified by sex, age, and setting. The study design was identical to that of the study conducted in 2011. Results: Of a total of 89,601 phone contacts, there were 6534 respondents. The average age was 61.5 years. With respect to smoking, 30.9% reported being former smokers and 14.7% were current smokers, 63.6% of whom reported having attempted to quit. Among the current smokers, 19.7% claimed to use electronic cigarettes, although 88% believe these pose a health risk. No significant differences were found in smoking prevalence or frequency of attempts to quit according to residential setting (rural/urban). The highest prevalence of current smoking in men was recorded in the 55–64 years age range (31.6%), while in women it was from 45 to 54 years (34.6%). Smoking has decreased with respect to 2011, from 21.1% to 16.1% in men and from 17.9% to 13.2% in women, with a clear variability according to region. Of the population surveyed, 32.5% had spontaneous knowledge about COPD, with significant geographic variability. The most frequent sources of information about the disease were social media and the Internet (39.6%), followed by the media (35.2%). Conclusions: The prevalence of tobacco use in adults has considerably decreased and there is greater knowledge about COPD in Spain, although there is significant variability according to region, which could explain the geographic variability in the prevalence of COPD. Strategies are needed to increase COPD education and awareness and to reinforce smoking prevention measures among women. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Consensus Document on the Overlap Phenotype COPD–Asthma in COPD

Author

Soler-Cataluña, Juan José, Cosío, Borja, Izquierdo, José Luis, López-Campos, José Luis, Marín, José M., Agüero, Ramón, Baloira, Adolfo, Carrizo, Santiago, Esteban, Cristóbal, Galdiz, Juan B., González, M. Cruz, Miravitlles, Marc, Monsó, Eduard, Montemayor, Teodoro, Morera, Josep, Ortega, Francisco, Peces-Barba, Germán, Puente, Luis, Rodríguez, José Miguel, Sala, Ernest, Sauleda, Jaume, Soriano, Joan B., and Viejo, José Luis

Published
2012
Full Text
View/download PDF

47. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine

Author

Carrasco-Hernández, Laura, Quintana-Gallego, Esther, Calero, Carmen, Reinoso-Arija, Rocío, Ruiz-Duque, Borja, López-Campos, José Luis, [Carrasco-Hernández,L, Quintana-Gallego,E, Calero,C, Reinoso-Arija,R, Ruiz-Duque,B, López-Campos,JL] Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain. [Carrasco-Hernández,L, and López-Campos,JL] Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Subjects
Moco, Inhibidores de fosfodiesterasa, Icenticaftor, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings], COPD, Enfermedad pulmonar obstructiva crónica, Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [Medical Subject Headings], Mucociliary clearance, Anatomy::Fluids and Secretions::Bodily Secretions::Mucus [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Phosphodiesterase Inhibitors [Medical Subject Headings], Organisms::Bacteria [Medical Subject Headings], Inflammation, Inflamación, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Protein S [Medical Subject Headings], Phenomena and Processes::Chemical Phenomena::Physicochemical Phenomena::Viscosity [Medical Subject Headings], Regulador de conductancia de transmembrana de fibrosis quística, Organisms::Viruses [Medical Subject Headings], CFTR modulators, Ivacaftor, Mucus, Depuración mucociliar, Phosphodiesterase inhibitors, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Membrane Transport Proteins::Ion Channels::Chloride Channels::Cystic Fibrosis Transmembrane Conductance Regulator [Medical Subject Headings], Cystic fibrosis transmembrane conductance regulator, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Respiratory System::Mucociliary Clearance [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Fluid Therapy [Medical Subject Headings]
Abstract

In recent years, numerous pathways were explored in the pathogenesis of COPD in the quest for new potential therapeutic targets for more personalised medical care. In this context, the study of the cystic fibrosis transmembrane conductance regulator (CFTR) began to gain importance, especially since the advent of the new CFTR modulators which had the potential to correct this protein's dysfunction in COPD. The CFTR is an ion transporter that regulates the hydration and viscosity of mucous secretions in the airway. Therefore, its abnormal function favours the accumulation of thicker and more viscous secretions, reduces the periciliary layer and mucociliary clearance, and produces inflammation in the airway, as a consequence of a bronchial infection by both bacteria and viruses. Identifying CFTR dysfunction in the context of COPD pathogenesis is key to fully understanding its role in the complex pathophysiology of COPD and the potential of the different therapeutic approaches proposed to overcome this dysfunction. In particular, the potential of the rehydration of mucus and the role of antioxidants and phosphodiesterase inhibitors should be discussed. Additionally, the modulatory drugs which enhance or restore decreased levels of the protein CFTR were recently described. In particular, two CFTR potentiators, ivacaftor and icenticaftor, were explored in COPD. The present review updated the pathophysiology of the complex role of CFTR in COPD and the therapeutic options which could be explored. Yes

Published
2021

49. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico

Author

Cosío, Borja G, Hernández, Carme, Chiner, Eusebi, Gimeno-Santos, Elena, Pleguezuelos, Eulogio, Seijas, Nuria, Rigau, David, López-Campos, José Luis, Soler-Cataluña, Juan José, Calle, Myriam, Miravitlles, Marc, Casanova, Ciro, and en nombre del equipo de trabajo de GesEPOC 2021

Subjects
Oxigenoterapia, Physical activity, Oxygen Inhalation Therapy, Oxygen therapy, Reducción de volumen pulmonar, Bronchodilator Agents, Oxygen, Pulmonary Disease, Chronic Obstructive, Lung transplantation, Trasplante pulmonar, Pulmonary Emphysema, Nutrición, Lung volume reduction, Rehabilitación pulmonar, Actividad física, Humans, Lung rehabilitation, Nutrition
Abstract

In addition to recommendations for pharmacological treatment stratified for risk and phenotype, the new 2021 edition of the Spanish COPD Guidelines (GesEPOC 2021) proposes a personalized approach to treatable traits, defined as a characteristic (clinical, physiological, or biological) that can be identified by diagnostic tests or biomarkers, for which a specific treatment is available. Some treatable traits, such as malnutrition, sedentarism, emphysema or respiratory failure, can be treated with non-pharmacological therapies, and this was not covered in detail in the guidelines. This section of GesEPOC 2021 includes a narrative update with recommendations on dietary treatment, physical activity, respiratory rehabilitation, oxygen therapy, non-invasive ventilation, volume reduction, and lung transplantation. A PICO question with recommendations on the use of supplemental oxygen during exercise in COPD patients without severe hypoxemia is also included.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results